Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to <18 Years of Age

Trial Profile

A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to <18 Years of Age

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Seqirus
  • Most Recent Events

    • 08 Aug 2018 Planned End Date changed from 30 Jul 2019 to 30 Jun 2019.
    • 13 Mar 2018 Planned End Date changed from 17 Mar 2019 to 30 Jul 2019.
    • 13 Mar 2018 Planned primary completion date changed from 17 Mar 2019 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top